OBJECTIVE: The International Mission on Prognosis and Analysis of Clinical Trials and Corticoid Randomisation After Significant Head injury prognostic models predict outcome after traumatic brain injury but have not been compared in large datasets. The objective of this is study is to validate externally and compare the International Mission on Prognosis and Analysis of Clinical Trials and Corticoid Randomisation after Significant Head injury prognostic models for prediction of outcome after moderate or severe traumatic brain injury. DESIGN: External validation study. PATIENTS: We considered five new datasets with a total of 9,036 patients, comprising three randomized trials and two observational series, containing prospectively collected individual traumatic brain injury patient data. MEASUREMENTS AND MAIN RESULTS: Outcomes were mortality and unfavorable outcome, based on the Glasgow Outcome Score at 6 months after injury. To assess performance, we studied the discrimination of the models (by area under the receiver operating characteristic curves), and calibration (by comparison of the mean observed to predicted outcomes and calibration slopes). The highest discrimination was found in the Trauma Audit and Research Network trauma registry (area under the receiver operating characteristic curves between 0.83 and 0.87), and the lowest discrimination in the Pharmos trial (area under the receiver operating characteristic curves between 0.65 and 0.71). Although differences in predictor effects between development and validation populations were found (calibration slopes varying between 0.58 and 1.53), the differences in discrimination were largely explained by differences in case mix in the validation studies. Calibration was good, the fraction of observed outcomes generally agreed well with the mean predicted outcome. No meaningful differences were noted in performance between the International Mission on Prognosis and Analysis of Clinical Trials and Corticoid Randomisation After Significant Head injury models. More complex models discriminated slightly better than simpler variants. CONCLUSIONS: Since both the International Mission on Prognosis and Analysis of Clinical Trials and the Corticoid Randomisation After Significant Head injury prognostic models show good generalizability to more recent data, they are valid instruments to quantify prognosis in traumatic brain injury.
OBJECTIVE: The International Mission on Prognosis and Analysis of Clinical Trials and Corticoid Randomisation After Significant Head injury prognostic models predict outcome after traumatic brain injury but have not been compared in large datasets. The objective of this is study is to validate externally and compare the International Mission on Prognosis and Analysis of Clinical Trials and Corticoid Randomisation after Significant Head injury prognostic models for prediction of outcome after moderate or severe traumatic brain injury. DESIGN: External validation study. PATIENTS: We considered five new datasets with a total of 9,036 patients, comprising three randomized trials and two observational series, containing prospectively collected individual traumatic brain injury patient data. MEASUREMENTS AND MAIN RESULTS: Outcomes were mortality and unfavorable outcome, based on the Glasgow Outcome Score at 6 months after injury. To assess performance, we studied the discrimination of the models (by area under the receiver operating characteristic curves), and calibration (by comparison of the mean observed to predicted outcomes and calibration slopes). The highest discrimination was found in the Trauma Audit and Research Network trauma registry (area under the receiver operating characteristic curves between 0.83 and 0.87), and the lowest discrimination in the Pharmos trial (area under the receiver operating characteristic curves between 0.65 and 0.71). Although differences in predictor effects between development and validation populations were found (calibration slopes varying between 0.58 and 1.53), the differences in discrimination were largely explained by differences in case mix in the validation studies. Calibration was good, the fraction of observed outcomes generally agreed well with the mean predicted outcome. No meaningful differences were noted in performance between the International Mission on Prognosis and Analysis of Clinical Trials and Corticoid Randomisation After Significant Head injury models. More complex models discriminated slightly better than simpler variants. CONCLUSIONS: Since both the International Mission on Prognosis and Analysis of Clinical Trials and the Corticoid Randomisation After Significant Head injury prognostic models show good generalizability to more recent data, they are valid instruments to quantify prognosis in traumatic brain injury.
Authors: Phil Edwards; Miguel Arango; Laura Balica; Rowland Cottingham; Hesham El-Sayed; Barbara Farrell; Janice Fernandes; Tamar Gogichaisvili; Nyoman Golden; Bennie Hartzenberg; Mazhar Husain; Mario Izurieta Ulloa; Zouheir Jerbi; Hussein Khamis; Edward Komolafe; Véronique Laloë; Gabrielle Lomas; Silke Ludwig; Guy Mazairac; Maria de los Angeles Muñoz Sanchéz; Luis Nasi; Fatos Olldashi; Patrick Plunkett; Ian Roberts; Peter Sandercock; Haleema Shakur; Caridad Soler; Reto Stocker; Petr Svoboda; Stefan Trenkler; N K Venkataramana; Jonathan Wasserberg; David Yates; Surakrant Yutthakasemsunt Journal: Lancet Date: 2005 Jun 4-10 Impact factor: 79.321
Authors: F Servadei; G D Murray; K Penny; G M Teasdale; M Dearden; F Iannotti; F Lapierre; A J Maas; A Karimi; J Ohman; L Persson; N Stocchetti; T Trojanowski; A Unterberg Journal: Neurosurgery Date: 2000-01 Impact factor: 4.654
Authors: Nikki van Leeuwen; Hester F Lingsma; Pablo Perel; Fiona Lecky; Bob Roozenbeek; Juan Lu; Haleema Shakur; James Weir; Ewout W Steyerberg; Andrew I R Maas Journal: Neurosurgery Date: 2012-04 Impact factor: 4.654
Authors: Pablo Perel; Miguel Arango; Tim Clayton; Phil Edwards; Edward Komolafe; Stuart Poccock; Ian Roberts; Haleema Shakur; Ewout Steyerberg; Surakrant Yutthakasemsunt Journal: BMJ Date: 2008-02-12
Authors: Ian Roberts; David Yates; Peter Sandercock; Barbara Farrell; Jonathan Wasserberg; Gabrielle Lomas; Rowland Cottingham; Petr Svoboda; Nigel Brayley; Guy Mazairac; Véronique Laloë; Angeles Muñoz-Sánchez; Miguel Arango; Bennie Hartzenberg; Hussein Khamis; Surakrant Yutthakasemsunt; Edward Komolafe; Fatos Olldashi; Yadram Yadav; Francisco Murillo-Cabezas; Haleema Shakur; Phil Edwards Journal: Lancet Date: 2004 Oct 9-15 Impact factor: 79.321
Authors: Nino A Mushkudiani; Chantal W P M Hukkelhoven; Adrián V Hernández; Gordon D Murray; Sung C Choi; Andrew I R Maas; Ewout W Steyerberg Journal: J Clin Epidemiol Date: 2008-04 Impact factor: 6.437
Authors: J T Lindsay Wilson; Frans J A Slieker; Valerie Legrand; Gordon Murray; Nino Stocchetti; Andrew I R Maas Journal: Neurosurgery Date: 2007-07 Impact factor: 4.654
Authors: Ewout W Steyerberg; Nino Mushkudiani; Pablo Perel; Isabella Butcher; Juan Lu; Gillian S McHugh; Gordon D Murray; Anthony Marmarou; Ian Roberts; J Dik F Habbema; Andrew I R Maas Journal: PLoS Med Date: 2008-08-05 Impact factor: 11.069
Authors: William C Walker; Adam P Sima; Jeanne M Hoffman; Cynthia Harrison-Felix; Amma A Agyemang; Katharine A Stromberg; Jennifer H Marwitz; Allen W Brown; Kristin M Graham; Randall Merchant; Jeffrey S Kreutzer Journal: J Neurotrauma Date: 2018-12-04 Impact factor: 5.269
Authors: Daniel Agustín Godoy; Andrés Rubiano; Alejandro A Rabinstein; Ross Bullock; Juan Sahuquillo Journal: Neurocrit Care Date: 2016-10 Impact factor: 3.210
Authors: Hester F Lingsma; John K Yue; Andrew I R Maas; Ewout W Steyerberg; Geoffrey T Manley Journal: J Neurotrauma Date: 2014-11-25 Impact factor: 5.269
Authors: Mypinder S Sekhon; Paul McBeth; Jie Zou; Lu Qiao; Leif Kolmodin; William R Henderson; Steve Reynolds; Donald E G Griesdale Journal: Neurocrit Care Date: 2014-10 Impact factor: 3.210